8 Medical Robotics Stocks Shaping the Future of Surgery

The intersection of artificial intelligence and healthcare is creating unprecedented opportunities in automated surgical platforms. Medical robotics is no longer a futuristic concept—it’s a rapidly expanding market segment that’s attracting significant investment attention. According to market research, the surgical robotics industry is projected to grow from approximately US$4.31 billion in 2024 to US$7.42 billion by 2030, driven by increasing demand for precision-guided surgical instruments and technological breakthroughs in minimally invasive procedures.

This growth trajectory reflects a fundamental shift in how surgeries are performed. Modern robotic platforms enable surgeons to perform complex procedures—from cardiac interventions to spinal corrections—with enhanced precision, reduced patient scarring, and faster recovery times. For investors tracking the healthcare technology space, understanding the key players in medical robotics stocks is essential.

The Market Drivers Behind Medical Robotics Growth

Procedure-specific innovations and advancements in automated surgical technology are fueling expansion across this sector. Hospitals and surgical centers worldwide are adopting robotic-assisted solutions to improve patient outcomes while reducing complications. This combination of clinical effectiveness and operational efficiency has positioned medical robotics as a cornerstone of modern surgical practices.

The publicly traded companies listed below represent the current landscape of medical robotics stocks, selected based on market capitalization and their clinical presence as of 2024.

1. Intuitive Surgical (NASDAQ:ISRG)

Market cap: US$171.48 billion | Share price: US$482.55

Standing as the global leader in automated surgical systems, Intuitive Surgical commands the market with its da Vinci platform. Since its introduction in 1999, the da Vinci system has become synonymous with robotic-assisted surgery, enabling over 10 million procedures across cardiac, thoracic, urological, gynecological, and colorectal applications.

The company continues to innovate within medical robotics stocks landscape. In 2023, the da Vinci SP received FDA approval for simple prostatectomy procedures, while 2024 saw clearance for the da Vinci 5, a next-generation multiport system. The installed base expanded significantly, reaching 9,203 systems globally and representing 14% annual growth. Integration of machine learning capabilities positions the company at the forefront of AI-enhanced surgical robotics.

2. Stryker (NYSE:SYK)

Market cap: US$138.59 billion | Share price: US$363.69

Stryker’s dominance in orthopedic robotics centers on the Mako platform, specifically designed for joint replacement procedures. The Mako system assists in partial knee, total knee, and total hip replacement surgeries with millimeter-level precision.

The company’s roadmap demonstrates aggressive expansion within medical robotics. The 2023 launch of Mako Total Knee 2.0 was followed by the introduction of Ortho Q Guidance, a fully autonomous knee and hip navigation system. In 2024, Stryker expanded Mako applications to shoulder and spine surgeries following FDA approvals, with CEO Kevin Lobo hinting at soft tissue surgical robotics under development. This trajectory solidifies Stryker’s position among leading medical robotics stocks.

3. Medtronic (NYSE:MDT)

Market cap: US$116.35 billion | Current share price: US$90.73

As one of the world’s largest medical device manufacturers, Ireland-based Medtronic entered the surgical robotics arena with its Hugo robot-assisted platform. First showcased through a prostatectomy procedure in Santiago, Chile, the Hugo system now collects clinical data through a dedicated patient registry supporting global regulatory submissions.

The company’s Hugo platform expanded into UK healthcare systems in 2023 and continues advancing through clinical trials. In 2024, Medtronic announced studies exploring Hugo applications in hernia repair and gynecological procedures, signaling broader surgical scope within medical robotics stocks.

4. Becton, Dickinson and Company (NYSE:BDX)

Market cap: US$68.04 billion | Share price: US$235.39

While Becton Dickinson manufactures medical devices and diagnostic systems rather than surgical robots directly, the company’s involvement in medical robotics stems from its strategic investment. In 2021, BD participated in the US$1.1 billion funding round for next-generation medical robotics company Vicarious Surgical.

Additionally, BD’s Cato software solution integrates robotic compounding devices into existing hospital IT infrastructure, with successful implementations across European facilities. This dual positioning—both investor and technology enabler—demonstrates BD’s commitment to the medical robotics sector.

5. Zimmer Biomet Holdings (NYSE:ZBH)

Market cap: US$21.39 billion | Share price: US$105.02

Zimmer Biomet’s ROSA robotics platform represents a multi-application approach to surgical automation. The platform encompasses the ROSA ONE Brain for complex neurosurgical planning and execution, alongside the ROSA Knee system for minimally invasive total knee replacements.

Leveraging data analytics and artificial intelligence, ROSA assists surgeons with real-time insights during procedures. This comprehensive portfolio positions Zimmer Biomet as a diversified player in medical robotics stocks, extending beyond orthopedic specialization into neurosurgery.

6. Smith & Nephew (NYSE:SNN)

Market cap: US$13.77 billion | Current share price: US$31.64

Smith & Nephew entered the surgical robotics market through two distinct platforms. The Navio system supports knee replacement procedures in both partial and total applications, while the handheld CORI robotic platform—launched in 2021—provides FDA-cleared solutions for unicompartmental and total knee replacement.

The company expanded its offerings with the CORIOGRAPH Pre-Operative Planning and Modeling Services in 2024, designed specifically for total knee arthroplasty procedures. This commitment to surgical planning integration highlights Smith & Nephew’s broader vision within medical robotics stocks.

7. Globus Medical (NYSE:GMED)

Market cap: US$9.41 billion | Current share price: US$69.48

Globus Medical specializes in spinal and orthopedic surgical solutions through its ExcelsiusGPS robotic navigation platform. The system demonstrates measurable advantages—increased accuracy, reduced radiation exposure, and shorter procedure times compared to conventional spine surgery.

The company’s strategic acquisition of NuVasive in 2023 (US$3 billion all-stock transaction) significantly expanded its market position. In 2024, Globus received FDA clearance for the ExcelsiusFlex reconstructive orthopedic robot, accelerating its growth trajectory in medical robotics stocks and positioning it for expansion into global hip and knee markets.

8. Procept BioRobotics (NASDAQ:PRCT)

Market cap: US$3.996 billion | Current share price: US$76.94

San Jose-based Procept BioRobotics pioneered autonomous tissue removal technology through its AquaBeam system for benign prostatic hyperplasia treatment. The company represents a specialized but rapidly growing niche within medical robotics stocks.

In August 2024, Procept secured FDA clearance for HYDROS, an AI-powered next-generation platform marking a significant technological leap. The company has installed over 400 robotic systems across U.S. surgical centers, with CEO Reza Zadno highlighting this milestone as pivotal for aquablation therapy adoption. Procept’s focused approach demonstrates how specialized medical robotics companies can achieve substantial market presence.

Investment Considerations in Medical Robotics

The landscape of medical robotics stocks reflects diverse strategies: from market-dominating leaders like Intuitive Surgical to specialized innovators like Procept BioRobotics. Each company targets different surgical specialties—orthopedics, neurosurgery, cardiology, and urology—suggesting a market with room for multiple winners.

Market growth projections through 2030 underscore the sector’s expansion potential, driven by aging populations, rising demand for minimally invasive procedures, and continuous technological improvements. As artificial intelligence and machine learning integration accelerates, medical robotics stocks will likely attract increasing institutional attention and capital allocation.

The diversity of revenue models and clinical applications across these companies provides investors with varied exposure to the medical robotics growth narrative, from established market leaders to emerging specialists gaining FDA clearance and clinical adoption.